![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}
An in-vitro diagnostics company that makes rapid, immunofluorescence, molecular and blood-glucose testing platforms and reagents covering screening through confirmatory testing.
Point-of-care molecular diagnostics system that automates nucleic acid extraction, amplification and result analysis in a single cartridge; M10 revenue rose 87% to 22 billion won in the first half of 2026, led by tuberculosis tests.
Two latent tuberculosis tests based on interferon-gamma release assays (IGRA): the ELISA product for high-volume testing and the FIA product for point-of-care use, delivering results in about 15 minutes.
Product families for rapid tests (STANDARD Q), multi-parameter fluorescence immunoassay (STANDARD F), ELISA for mass screening (STANDARD E) and fully automated chemiluminescence immunoassay (STANDARD i), plus blood glucose meters (BGMS).
U.S. diagnostics subsidiary acquired in 2023; the company also has overseas subsidiaries in India, Indonesia, Brazil, Italy and Germany, among others.
STANDARD M10 MTB-RIF/INH, which detects tuberculosis bacteria and rifampicin and isoniazid resistance genes in about 99 minutes, was added to the Global Fund's procurement list for TB molecular diagnostics.
The latent TB tests STANDARD E TB-Feron ELISA and STANDARD F TB-Feron FIA were added to the Global Fund's procurement list for interferon-gamma release assays.
Official role guide
Observed 2026-10-25
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.